Recursion Pharmaceuticals, Inc. (RXRX): R&D Expense
$475.27M
Year ended 2025-12-31
$394.51M
Trailing 12 months to 2026-06-30
+45.1%
3-year compound annual growth
+49.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $475.27M | +51.2% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $314.42M | +30.3% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $241.23M | +54.9% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $155.70M | +15.1% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $135.27M | +113.6% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $63.32M | +38.2% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $45.81M | n/a | 2022-03-23, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $475.27M | +51.2% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $117.69M | -15.0% |
| Compugen Ltd (CGEN) | 2025-12-31 | $22.76M | -8.3% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $33.56M | -34.6% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $455.97M | -10.0% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $129.62M | +8.5% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $195.70M | +38.5% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $9.08M | +33.1% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $166.42M | -34.0% |
Compare RXRX, AUTL, CGEN, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗